玛莱克琳生物技术公司Moleculin Biotech, Inc. （MBRX） 2018年年度报告「NASDAQ」.pdf

1、2018Annual ReportGroundbreakingCancer TherapiesMoleculin is a clinical stage pharmaceutical company focused on the treatment of highly resistant cancers.These resistant cancers range from deadly glioblastoma brain tumors to acute myeloid leukemia,pancreatic cancer,among others.Our diverse pipeline o

2、f technologies was built around the recognition that treatment resistant tumors tend to have a common set of traits,including specific multidrug resistant mechanisms,an evasion of the natural immune system,a marked upregulation of certain key oncogenic transcription factors and an increased dependen

3、ce on glycolysis for energy production.Each of these elements is addressed by the unique and innovative mechanisms introduced by one or more of our three core technologies.We believe this approach not only provides the opportunity to help the many patients in need of new,more effective therapies,but

4、 also to work in combination with numerous existing drugs that often inevitably fail as tumors present immediate or acquired resistance.By focusing on targeting such significant unmet needs in highly resistant cancers,we believe we not only provide new hope to cancer patients,but also present our sh

5、areholders with an important strategic advantage.Showing even modest improvements in highly resistant cancers can lead to accelerated approval pathways,reducing the time and capital required to ultimately realize success.On the strength of our successful clinical preparation in 2018,we enter 2019 wi

6、th a great deal of momentum with our clinical trials.2018 was very exciting as we gained regulatory consent to commence our initial trials for our lead drug candidate Annamycin and our STAT3 inhibiting Immune/Transcription Modulator,WP1066.We believe that 2019 will be the“year of data,”as we report